Abstract 2660
Background
MPM is a highly aggressive pleural tumor associated with asbestos exposure and with limited survival despite systemic therapy. The incidence of MPM in elderly is increasing and these patients (p) require special consideration due to multiple comorbidities and increased risk of toxicities. The objective of this study is to characterize elderly p diagnosed with MPM at our institution and evaluate overall survival in this population.
Methods
One hundred forty-seven MPM p diagnosed at Vall d´Hebron Institute of Oncology between November 2002 and December 2016 were reviewed. Associations between clinical variables and outcome were assessed with Cox regression models and survival data were calculated by the Kaplan-Meier method.
Results
Patient’s characteristics: median age 68 years (y) (51-86 years), males: 70%, performance status (PS)1: 67%, asbestos exposure: 72%, epithelioid subtype: 73%. First line chemotherapy was offered to 83% of p (73% cisplatin-pemetrexed and 21% carboplatin-pemetrexed). Median progression free survival (PFS) first line was 4.9 months (m;CI95% 3.6-5.6). Clinical trial was offered as second-line regimen in 34%. Median survival (OS) in overall population was 16.8 m (95%CI13.2-22.2) and in those treated with chemotherapy was 20.6 m (95%17.1-23.6). Epitheliod histology, PS 0, neutrophil-lymphocyte ratio >5 and treatment with cisplatin vs carboplatin were associated with significant improvements in OS. In total, 59 p were >70y, 42 p > 75y and 19 p > 80y. Elderly p (>70y) received first line in 66% of cases, with carboplatin-pemetrexed in 76%. Median PFS in first line was 4.8 m (95%CI 3.7-4.7m). No differences in treatment discontinuation by toxicity neither dose reductions were found (6% vs 4% and 6 vs 7% in elderly vs < 70y, respectively). Second line was given in 42% of elderly. Median OS in elderly p receiving chemotherapy was 15.1 m vs 2.7 m with best supportive care (p < 0.001). Epithelioid histology, PS 0 and eligibility to first line chemotherapy were significant prognostic factors in elderly p (p < 0.001).
Conclusions
In our real world experience, chemotherapy was feasible in most elderly p with MPM and does not associates with inferior outcomes or higher toxicity compared to younger population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
S. Cedres: Advisory / Consultancy, Travel / Accommodation / Expenses: Roche; Advisory / Consultancy: Bristol-Myers Squibb; Speaker Bureau / Expert testimony: Boehringer Ingelheim; Advisory / Consultancy, Travel / Accommodation / Expenses: Pfizer; Speaker Bureau / Expert testimony: Apmhera; Advisory / Consultancy: Lilly; Honoraria (institution): Merck. P. Iranzo: Advisory / Consultancy: Roche; Advisory / Consultancy: Grunenthal; Advisory / Consultancy, Travel / Accommodation / Expenses: Kyowa Kirin; Advisory / Consultancy: Rovi; Advisory / Consultancy, Travel / Accommodation / Expenses: MSD; Advisory / Consultancy, Travel / Accommodation / Expenses: Pierre Fabre. A. Callejo: Advisory / Consultancy: Roche ; Advisory / Consultancy: Pfizer; Travel / Accommodation / Expenses: MSD; Advisory / Consultancy: Boehringer Ingelheim; Advisory / Consultancy: Bristol-Myers Squibb. N. Pardo: Advisory / Consultancy, Travel / Accommodation / Expenses: roche; Advisory / Consultancy, Travel / Accommodation / Expenses: Pfizer; Advisory / Consultancy: Boehringer Ingelheim; Advisory / Consultancy: Bristol Myers Squibb. A. Navarro: Advisory / Consultancy: Roche; Advisory / Consultancy, Travel / Accommodation / Expenses: Pfizer; Advisory / Consultancy, Travel / Accommodation / Expenses: Boehringer Ingelheim; Advisory / Consultancy: Bristol-Myers Squibb ; Speaker Bureau / Expert testimony: Orizon Genomics. A. Martinez-Marti: Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Roche ; Advisory / Consultancy, Travel / Accommodation / Expenses: MSD; Advisory / Consultancy: Pfizer; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Boehringer Ingelheim ; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Bristol-Myers Squibb; Advisory / Consultancy, Travel / Accommodation / Expenses: Merck Sharp. R. Dienstmann: Advisory / Consultancy, Speaker Bureau / Expert testimony: Roche; Advisory / Consultancy: Novartis; Speaker Bureau / Expert testimony: Symphogen; Speaker Bureau / Expert testimony: Ipsen; Speaker Bureau / Expert testimony: Amgen; Speaker Bureau / Expert testimony: Sanofi; Speaker Bureau / Expert testimony: MSD; Speaker Bureau / Expert testimony: Servier; Research grant / Funding (institution): Merck. E. Felip: Advisory / Consultancy, Speaker Bureau / Expert testimony: Abbvie; Advisory / Consultancy, Speaker Bureau / Expert testimony: AstraZeneca; Advisory / Consultancy: Blue Print Medicines; Advisory / Consultancy, Speaker Bureau / Expert testimony: Boehringer Ingelheim; Advisory / Consultancy: Celgene; Advisory / Consultancy, Speaker Bureau / Expert testimony: Eli Lilly; Advisory / Consultancy: guardant health ; Advisory / Consultancy, Speaker Bureau / Expert testimony: Merck KgaA; Advisory / Consultancy, Speaker Bureau / Expert testimony: Merck, Sharp and Dohme; Advisory / Consultancy, Speaker Bureau / Expert testimony: Novartis; Advisory / Consultancy, Speaker Bureau / Expert testimony: Pfizer; Advisory / Consultancy, Speaker Bureau / Expert testimony: Roche; Advisory / Consultancy, Speaker Bureau / Expert testimony: Takeda; Advisory / Consultancy: Janssen. All other authors have declared no conflicts of interest.
Resources from the same session
5011 - LCSCAF1 maintains cancer stem-like traits by stabilizing c-Myc protein and promotes metastasis and recurrence in lung cancer
Presenter: Tao Guo
Session: Poster Display session 1
Resources:
Abstract
4955 - XAF1 Enhances Temozolomide Induced Autophagic Cell Death through AMPK signaling pathway
Presenter: Mingoo Lee
Session: Poster Display session 1
Resources:
Abstract
5616 - The effect of cortisol on methylation patterns in breast cancer cell lines
Presenter: Haya Intabli
Session: Poster Display session 1
Resources:
Abstract
4649 - Global and sex-specific epigenome-wide association studies for the identification of the main methylated loci related to smoking in a Mediterranean population
Presenter: Judith Begona Ramirez Sabio
Session: Poster Display session 1
Resources:
Abstract
4984 - Whole transcriptomics analyses of mimicking Circulating Tumor Cells (CTCs) by single-cell RNA sequencing (scRNAseq)
Presenter: Jessica Garcia
Session: Poster Display session 1
Resources:
Abstract
5926 - Comparison of enzymatic- and bisulfite conversion to map the plasma cell-free methylome in cancer
Presenter: Nicole Lambert
Session: Poster Display session 1
Resources:
Abstract
5454 - Detection of low mutations in hepatocellular carcinoma by using circulating tumor DNA
Presenter: Esl Kim
Session: Poster Display session 1
Resources:
Abstract
4428 - Variants in the JAK1 and JAK2 genes in the risk and prognosis of patients with cutaneous melanoma
Presenter: Bruna Carvalho
Session: Poster Display session 1
Resources:
Abstract
4409 - P-Rex1 expression in breast cancer patients.
Presenter: Angela Lara Montero
Session: Poster Display session 1
Resources:
Abstract
4185 - Modulation of Risk of Cutaneous Melanoma Patients by Variants in STAT3 Gene and Functional Analysis
Presenter: Gabriela Gomez
Session: Poster Display session 1
Resources:
Abstract